This Article Full Text Full Text (PDF) Supplementary Data All Versions of this Article: 0008-5472.CAN-07-1068v1 67/16/7893    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Roth, T. J. Articles by Kwon, E. D. Search for Related Content PubMed PubMed Citation Articles by Roth, T. J. Articles by Kwon, E. D.

B7-H3 Ligand Expression by Prostate Cancer: A Novel Marker of Prognosis and Potential Target for Therapy

Departments of ¹ Urology, ² Health Sciences Research, ³ Immunology, and ⁴ Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota

Requests for reprints: Eugene D. Kwon, Departments of Urology and Immunology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905. Phone: 507-284-5365; Fax: 507-284-1637; E-mail: kwon.eugene{at}mayo.edu.

B7 coregulatory ligands can be aberrantly expressed in human disease. In the context of cancer, these ligands may act as antigen-specific inhibitors of T-cell–mediated antitumoral immunity. We recently reported that B7-H1 expression by carcinomas of the kidney and bladder portends aggressive disease and diminished survival. The expression of these proteins in prostate cancer, however, has not been investigated. We evaluated B7-H3 and B7-H1 protein expression in the pathologic specimens of 338 men treated for clinically localized prostate cancer between 1995 and 1998 with radical retropubic prostatectomy. Expression levels of B7-H3 in prostate cancer were correlated with pathologic indicators of aggressive cancer as well as clinical outcome. We report that B7-H3 is uniformly and aberrantly expressed by adenocarcinomas of the prostate, high-grade prostatic intraepithelial neoplasia, and four prostate cancer cell lines, whereas B7-H1 is rarely expressed. B7-H3 is expressed by benign prostatic epithelia, although at a more reduced level relative to neoplastic tissue. Increasing levels of B7-H3 intensity correlate with worsening clinicopathologic features of prostate cancer. Marked B7-H3 intensity, present in 67 (19.8%) specimens, confers a >4-fold increased risk of cancer progression after surgery (risk ratio, 4.42; P < 0.001). A survey of normal tissues revealed that B7-H3 is expressed within the liver, urothelium, and fetal kidney. In summary, B7-H3 is aberrantly expressed in all prostate cancers and represents an independent predictor of cancer progression following surgery. Moreover, B7-H3 encompasses a novel diagnostic and potential therapeutic target for the clinical management of prostate cancer and, perhaps, other malignancies as well. [Cancer Res 2007;67(16):7893–900]

This article has been cited by other articles:

				H. Xu, I. Y. Cheung, H.-F. Guo, and N.-K. V. Cheung MicroRNA miR-29 Modulates Expression of Immunoinhibitory Molecule B7-H3: Potential Implications for Immune Based Therapy of Human Solid Tumors Cancer Res., August 1, 2009; 69(15): 6275 - 6281. [Abstract] [Full Text] [PDF]

				I. Mercier, M. C. Casimiro, J. Zhou, C. Wang, C. Plymire, K. G. Bryant, K. M. Daumer, F. Sotgia, G. Bonuccelli, A. K. Witkiewicz, et al. Genetic Ablation of Caveolin-1 Drives Estrogen-Hypersensitivity and the Development of DCIS-Like Mammary Lesions Am. J. Pathol., April 1, 2009; 174(4): 1172 - 1190. [Abstract] [Full Text] [PDF]

				G. Chavin, Y. Sheinin, P. L. Crispen, S. A. Boorjian, T. J. Roth, L. Rangel, M. L. Blute, T. J. Sebo, D. J. Tindall, E. D. Kwon, et al. Expression of Immunosuppresive B7-H3 Ligand by Hormone-Treated Prostate Cancer Tumors and Metastases Clin. Cancer Res., March 15, 2009; 15(6): 2174 - 2180. [Abstract] [Full Text] [PDF]

				B. D. Lehmann, M. S. Paine, A. M. Brooks, J. A. McCubrey, R. H. Renegar, R. Wang, and D. M. Terrian Senescence-Associated Exosome Release from Human Prostate Cancer Cells Cancer Res., October 1, 2008; 68(19): 7864 - 7871. [Abstract] [Full Text] [PDF]

				P. L. Crispen, Y. Sheinin, T. J. Roth, C. M. Lohse, S. M. Kuntz, X. Frigola, R. H. Thompson, S. A. Boorjian, H. Dong, B. C. Leibovich, et al. Tumor Cell and Tumor Vasculature Expression of B7-H3 Predict Survival in Clear Cell Renal Cell Carcinoma Clin. Cancer Res., August 15, 2008; 14(16): 5150 - 5157. [Abstract] [Full Text] [PDF]

				S. A. Boorjian, Y. Sheinin, P. L. Crispen, S. A. Farmer, C. M. Lohse, S. M. Kuntz, B. C. Leibovich, E. D. Kwon, and I. Frank T-Cell Coregulatory Molecule Expression in Urothelial Cell Carcinoma: Clinicopathologic Correlations and Association with Survival Clin. Cancer Res., August 1, 2008; 14(15): 4800 - 4808. [Abstract] [Full Text] [PDF]

				M. Hashiguchi, H. Kobori, P. Ritprajak, Y. Kamimura, H. Kozono, and M. Azuma From the Cover: Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses PNAS, July 29, 2008; 105(30): 10495 - 10500. [Abstract] [Full Text] [PDF]

				K. A. Hofmeyer, A. Ray, and X. Zang The contrasting role of B7-H3 PNAS, July 29, 2008; 105(30): 10277 - 10278. [Full Text] [PDF]

				X. Zang, R. H. Thompson, H. A. Al-Ahmadie, A. M. Serio, V. E. Reuter, J. A. Eastham, P. T. Scardino, P. Sharma, and J. P. Allison B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome PNAS, December 4, 2007; 104(49): 19458 - 19463. [Abstract] [Full Text] [PDF]